ARTICLE SUMMARY:
Heartflow, a trailblazer in AI-driven coronary artery disease prediction, is on the cusp of major expansion, following its oversubscribed IPO and newly secured insurance coverage from major commercial players. The company’s innovative imaging platform, designed to assess CAD, is poised for widespread adoption.
While AI’s application in coronary artery disease is a recent buzz in the medical community, Heartflow has been addressing this challenge since its inception in 2007—well ahead of competitors like Cleerly and Caristo Diagnostics. Now, the company’s pioneering approach is beginning to pay off, with several key milestones marking its ascent.
In August 2025, Heartflow went public with an oversubscribed IPO, raising a hefty $364.2 million and achieving a market capitalization of nearly $3 billion. This was the second-largest medtech IPO of the year, trailing only the Caris Life Sciences oncology-focused offering.
